First step: testing new drug combo for Tough-to-Treat rare cancers
NCT ID NCT01046487
Summary
This study aimed to find the safest dose of a drug called imatinib when given with a low, continuous dose of another drug, cyclophosphamide. It was for people with rare, advanced cancers that had spread or could not be removed by surgery and had no standard treatment options. The main goal was to see how much of the drug combination patients could tolerate without severe side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Léon Bérard
Lyon, 69008, France
-
Centre Oscar Lambret
Lille, 59020, France
-
Institut Bergonié
Bordeaux, 33076, France
Conditions
Explore the condition pages connected to this study.